Table 1 Patient and tumor characteristics
Characteristic | Arm 1 (n = 63) | Arm 2 (n = 57) | P value |
|---|---|---|---|
n (%) | n (%) | ||
Median age | 55.0 years (IQR:45.0–64.0) | 54 .0 years (IQR:48.5–62.5) | 0.948 |
FIGO stage (2009) | 0.668 | ||
IB2 | 2 (3.2%) | 3 (5.3%) | |
IIA1 | 1 (1.6%) | 4 (7.0%) | |
IIA2 | 8 (12.7%) | 6 (10.5%) | |
IIB | 30 (47.6%) | 24 (42.1%) | |
IIIA | 3 (4.8%) | 3 (5.3%) | |
IIIB | 12 (19.0%) | 11 (19.3%) | |
IVA | 5 (7.9%) | 3 (5.3%) | |
IVB | 2 (3.2%) | 3 (5.3%) | |
Histology | 0.844 | ||
Squamous cell carcinoma | 58 (92.1%) | 54 (94.7%) | |
Non-squamous cell carcinoma | 5 (7.9%) | 3 (5.3%) | |
Concurrent chemotherapy | 0.608 | ||
Yes | 52 (82.5%) | 49 (86.0%) | |
No | 11 (17.7%) | 8 (14.0%) | |
EBRT spot | 0.949 | ||
In our hospital | 35 (55.6%) | 32 (56.1%) | |
In other hospitals | 28 (44.4%) | 25 (43.9%) | |
Median OTT1 | 64.0 days (IQR:57.0–85.0) | 60.0 days (IQR:52.5–66.0) | 0.006 |
EBRT in our hospital | 59 days (IQR:54.0–63.0) | 54.5 days (IQR:50.0–61.75) | 0.026 |
EBRT in other hospitals | 86 days (IQR:78.0–117.5) | 65 days (IQR:63.0–83.5) | 0.001 |